Sunitinib malate

Sunitinib malate, 341031-54-7, SU011248 L-malate salt, PHA-290940AD, sunitinib L-malate, SU010398, SU-011248 L-malate salt, LVX8N1UT73, DTXSID4046492, SU-010398, DTXCID801476195, NSC736511, 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1), 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1), RefChem:56081, Sutent, Sunitinib malate [USAN], MFCD08282795, Sunitinib (Malate), (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, (2S)-2-hydroxybutanedioic acid, SU 11248, CAS-341031-54-7, NCGC00164631-01, UNII-LVX8N1UT73, SU 011248, Sutent, , C26H33FN4O7, PDGF TK antagonist, Sutent (TN), Sutent (TN) (Pfizer), Sunitinib Malate (Sutent), CHEMBL1567, SU-11248 L-malate salt, SUNITINIB MALATE [MI], Sunitinib malate (JAN/USAN), SUNITINIB MALATE [JAN], orb1310676, SCHEMBL1258610, Sunitinib (Malate) (Standard), SCHEMBL29371243, SUNITINIB MALATE [VANDF], SUNITINIB MALATE [MART.], CHEBI:232546, PNU-290940AD, SUNITINIB MALATE [WHO-DD], HMS3261H09, HMS6018J17, Sunitinib malate, >=98% (HPLC), Tox21_112249, Tox21_500514, HY-10255R, s1042, SU-11248J, Sunitinib malate - Bio-X trade mark, AKOS005145765, AKOS025149097, Sunitinib Malate (Sunitinib L-Malate), SUNITINIB MALATE [ORANGE BOOK], Tox21_112249_1, CCG-221818, CS-0177, EBC-218028, FS10822, KS-5023, NCGC00164631-05, NCGC00261199-01, BP-43644, BS164428, HY-10255, MS-33338, SY075040, SU-11248, , SW219407-1, D06402, Q27283213, (2S)-2-Hydroxybutanedioic acid--N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1/1), (2S)-2-hydroxybutanedioic acid, N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide, (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(S)-2-hydroxysuccinate, 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1), 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1), 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, malate salt, N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Malate, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, (2S)-2-hydroxybutanedioic acid